|Bid||10.41 x 1100|
|Ask||10.42 x 2200|
|Day's Range||10.34 - 10.67|
|52 Week Range||5.27 - 18.50|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.96|
Paladin Labs Inc. Announces Approval of Envarsus PA™ (tacrolimus prolonged-release tablets) in Canada
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo International PLC NASDAQ/NGS:ENDPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ENDP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $18.71 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Endo International said Thursday it will not oppose a request by the Food and Drug Administration for a further stay through March 15 of the company's ongoing litigation against the federal agency. The litigation challenges the FDA's process for allowing the bulk compounding of certain drugs, including vasopressin, that have not satisfied the legal requirements of the Drug Quality and Security Act amendments to the Federal Food, Drug, and Cosmetic Act. One of Endo's subsidiaries, Par Sterile Products of Chestnut Ridge, N.Y., manufacturers Vasostrict, the only vasopressin product currently approved by the FDA. Vasostrict is approved as a treatment for raising blood pressure in patient with septic shock. Two Endo subsidiaries, Par and Endo Par Innovation Co., sued the FDA in October 2017 challenging the agency's "interim policy" on bulk compounding.
DUBLIN , Feb. 7, 2019 /PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today announced that the U.S. Food and Drug Administration (the "FDA") has requested a further ...
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
DUBLIN, Jan. 25, 2019 /PRNewswire/ -- Endo International plc (ENDP) will announce its fourth-quarter and full-year 2018 financial results on February 28, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open. A simultaneous webcast of the call can be accessed by visiting http://investor.endo.com/events-and-presentations. Endo International plc (ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization.
The municipalities allege that the companies misled health care providers about addiction risks of opioids, leading to abuse of opioids in their communities.
The Food and Drug Administration earlier this week requested a further stay of Endo International's ongoing litigation against the federal agency for the duration of the federal government's partial shutdown. Endo (NASDAQ: ENDP), which is based in Dublin, Ireland, and has its U.S. headquarters in Malvern, PA., sued the FDA in October 2017 alleging the agency acted improperly and in violation of federal statutes in authorizing the bulk compounding of certain drugs, including vasopressin. Compounding in the pharmaceutical industry refers to when an existing drug's ingredients are altered or combined with other ingredients to create a medication that is specifically tailored to an individual patient’s needs.
Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.
DUBLIN , Dec. 31, 2018 /PRNewswire/ -- Endo International plc ("Endo"; NASDAQ: ENDP) today announced that, due to the ongoing federal government shutdown, the U.S. Food and Drug Administration ...
DUBLIN , Dec. 19, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference in San Francisco, California ...
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has signed a Definitive Agreement with Endo International plc's (ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril® (vigabatrin) tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment, milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.
Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]
Endo International PLC (NASDAQ: ENDP) stock dropped 8.53 percent Friday after “60 Minutes” announced it will be featuring attorney general and Ohio governor-elect Mike DeWine on Sunday’s episode. What Happened? “60 Minutes,” which has been known to move markets with its exposes, announced that Sunday’s episode of the show will be focused on “shocking” data DeWine has uncovered that's related to opioid distribution. Endo is one of the companies included in lawsuits in Ohio, Missouri and Mississippi related to its role in the opioid epidemic.
BOSTON, MA / ACCESSWIRE / December 14, 2018 / Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether Endo International PLC ("Endo" ...
Endo International shares slid 8 percent as a '60 Minutes' report on data collected by opioid distributors regarding the amounts and destinations of painkillers is set to air Sunday.
Endo International shares fell 8 percent after news of a report by CBS' "60 Minutes" about data collected by opioid distributors on amounts and destinations of painkillers. The data tracking amounts and destinations of painkillers were part of a confidential reporting system distributors shared with the Drug Enforcement Agency, the report, which is slated to air Sunday, says.
The treatment is a reformulated version of the company's commonly abused painkiller Roxicodone, intended to make the drug less desirable and more difficult to be abused by snorting or injecting. Mallinckrodt's shares fell 4.4 percent to $20.02 in premarket trading on Wednesday. The decision comes after an advisory panel to the FDA voted 10-7 in favor of the drug, saying it should be labeled as abuse deterrent only by the nasal route.
In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.